content top

Surgical Displacement of Medium-Sized Submacular Hemorrhage

Posted by on Oct 1, 2009 in Submacular Haemorrhage

http://www.evrs.eu/medias/2009/congress/Hemorrhages.flv Author: Sophie J. Bakri, Rochester, MN, USA Advantages: Surgical displacement of medium-sized thick submacular hemorrhage has the advantage of minimizing the toxic effects of blood on the retina. Methods: Pars plana vitrectomy, subretinal tPA and air-fluid exchange is performed. The patient lies flat on his back for 30 minutes, then upright for the next 24 hours. Effectiveness /...

Read More

Vitrectomy Session – Silicone

Posted by , , , , , , , , , , , and on Oct 1, 2007 in Complication - Toxicity, Silicone oil, Vitrectomy

http://www.evrs.eu/medias/2007/videos/vitrectomysession-silicone.flv

Read More

Stability of Bevacizumab (Avastin) after Withdrawal into a Syringe and Refrigeration or Freezing

Posted by , , , , , and on Oct 1, 2006 in Bevacizumab Avastin, Experimental Study

Colin A. McCannel, MD (Rochester, MN), Sophie J. Bakri, MD (Rochester, MN), Melissa R. Snyder, PhD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Michael W. Stewart, MD (Jacksonville, FL), Frederick J. Troendle, PhD (Jacksonville, FL), William T. Weiss, (Rochester, MN), Ravinder J. Singh, PhD (Rochester, MN) PURPOSE: To assess the stability of bevacizumab (Avastin) over time after withdrawal into a syringe and refrigeration or...

Read More

Pharmacokinetics of Intravitreal Bevacizumab (Avastin)

Posted by , , , and on Oct 1, 2006 in Bevacizumab Avastin, Experimental Study

http://www.evrs.eu/medias/2006/congress/Pharmacokinetics-of-Intravitreal-Bevacizumab-(Avastin).swf Sophie J Bakri, MD (Cleveland, OH), Melissa Snyder, PhD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Joel Reid, PhD (Rochester, MN), Ravinder Singh, PhD (Rochester, MN) PURPOSE: To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (avastin). METHODS: 1.25 mg (0.05cc) of bevacizumab was injected into the vitreous...

Read More

Absence of Histologic Retinal Toxicity with Standard Clinical Doses of Intravitreal Bevacizumab in a Rabbit Model

Posted by , , , and on Oct 1, 2006 in Bevacizumab Avastin, Complication - Toxicity, Experimental Study

Sophie J Bakri, MD (Cleveland, OH), J.D. Cameron, MD (Rochester, MN), Jose S. Pulido, MD (Rochester, MN), Colin A. McCannel, MD (Rochester, MN), Ronald Marler, DVM, PhD (Scottsdale, AZ) PURPOSE: To evaluate the retinal toxicity of intravitreal bevacizumab in an animal model. METHODS: Bevacizumab was injected into the vitreous of one eye of each of 8 Dutch-belted rabbits; the other eye served as a control. Four rabbits received a dose of...

Read More
content top